Literature DB >> 17901082

Low-gradient aortic stenosis: impact of prosthesis-patient mismatch on survival.

Jean-Luc Monin1, Mehran Monchi, Matthias E W Kirsch, Hélène Petit-Eisenmann, Serge Baleynaud, Christophe Chauvel, Damien Metz, Catherine Adams, Jean-Paul Quere, Pascal Gueret, Christophe Tribouilloy.   

Abstract

AIMS: To assess the prognostic impact of prosthesis-patient mismatch (PPM) in a large consecutive series of patients operated for low-gradient aortic stenosis (AS). METHODS AND
RESULTS: Outcomes after surgery for low-gradient AS were prospectively assessed in 152 consecutive patients from seven institutions. There were 113 men (74%); mean age was 72 years (64-76); valve area, 0.7 cm(2) (0.6-0.8); left ventricular (LV) ejection fraction 0.31 (0.25-0.37) and baseline mean transaortic pressure gradient (MPG), 30 mmHg (25-35) Among 139 patients with available prosthetic valve effective orifice area (EOA), PPM (defined by an indexed EOA < or = 0.85 cm(2)/m(2)) was present in 79 patients (57%) and had no significant impact on post-operative mortality. Independent predictors of overall mortality were LV contractile reserve [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.35-0.78; P = 0.002], associated coronary artery bypass grafting (HR 1.87; 95% CI 1.24-2.82; P =0.003), baseline MPG (per 1 mmHg decrease to 10 mmHg; HR 1.03; 95% CI 1.01-1.06; P = 0.021), previous cancer (HR 2.13; 95% CI 1.05-4.29; P = 0.037), and logistic EuroSCORE (per 1% increase; HR 1.02; 95% CI 1.01-1.04; P = 0.040). CONCLUSION In this large multicentre series of patients with low-gradient AS, we found that PPM (moderate in most cases) had no influence on post-operative mortality. Therefore, the performance of more complex interventions in order to avoid moderate PPM may not be justified in the setting of low-gradient AS, because their higher risk probably outweighs the expected benefit.

Entities:  

Mesh:

Year:  2007        PMID: 17901082     DOI: 10.1093/eurheartj/ehm393

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Small prosthesis size in aortic valve replacement does not affect mortality.

Authors:  Damien J LaPar; Gorav Ailawadi; Castigliano M Bhamidipati; George Stukenborg; Ivan K Crosby; John A Kern; Irving L Kron
Journal:  Ann Thorac Surg       Date:  2011-09       Impact factor: 4.330

Review 2.  Update on aortic valve prosthesis-patient mismatch in Japan.

Authors:  Yoshimasa Sakamoto; Kazuhiro Hashimoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-04-13

3.  Patient-prosthesis mismatch in patients treated with transcatheter aortic valve implantation - predictors, incidence and impact on clinical efficacy. A preliminary study.

Authors:  Karol Zbroński; Bartosz Rymuza; Piotr Scisło; Kajetan Grodecki; Paulina Dobkowska; Marek Wawrzacz; Radosław Wilimski; Anna Słowikowska; Janusz Kochman; Krzysztof J Filipiak; Grzegorz Opolski; Zenon Huczek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-11-29       Impact factor: 1.426

4.  The effect of patient-prosthesis mismatch on survival after aortic and mitral valve replacement: a 10 year, single institution experience.

Authors:  Sudeep Das De; Ashok Nanjappa; Karim Morcos; Sadia Aftab; John Butler; Vivek Pathi; Philip Curry; Sukumaran Nair
Journal:  J Cardiothorac Surg       Date:  2019-12-06       Impact factor: 1.637

5.  Impact of prosthesis-patient mismatch on early and late mortality after aortic valve replacement.

Authors:  Bart M Koene; Mohamed A Soliman Hamad; Wobbe Bouma; Massimo A Mariani; Kathinka C Peels; Jan-Melle van Dantzig; Albert H van Straten
Journal:  J Cardiothorac Surg       Date:  2013-04-17       Impact factor: 1.637

6.  Can postoperative mean transprosthetic pressure gradient predict survival after aortic valve replacement?

Authors:  Bart M Koene; Mohamed A Soliman Hamad; Wobbe Bouma; Massimo A Mariani; Kathinka C Peels; Jan-Melle van Dantzig; Albert H van Straten
Journal:  Clin Res Cardiol       Date:  2013-10-18       Impact factor: 5.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.